258 related articles for article (PubMed ID: 26311843)
1. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
Doyle T; Dunn DT; Ceccherini-Silberstein F; De Mendoza C; Garcia F; Smit E; Fearnhill E; Marcelin AG; Martinez-Picado J; Kaiser R; Geretti AM;
J Antimicrob Chemother; 2015 Nov; 70(11):3080-6. PubMed ID: 26311843
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
[TBL] [Abstract][Full Text] [Related]
3. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
[TBL] [Abstract][Full Text] [Related]
4. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
[TBL] [Abstract][Full Text] [Related]
9. Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.
Llácer Delicado T; Torrecilla E; Holguín Á
J Antimicrob Chemother; 2016 Feb; 71(2):362-6. PubMed ID: 26546669
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
[TBL] [Abstract][Full Text] [Related]
11. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
[TBL] [Abstract][Full Text] [Related]
13. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
14. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
[TBL] [Abstract][Full Text] [Related]
15. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
Armenia D; Vandenbroucke I; Fabeni L; Van Marck H; Cento V; D'Arrigo R; Van Wesenbeeck L; Scopelliti F; Micheli V; Bruzzone B; Lo Caputo S; Aerssens J; Rizzardini G; Tozzi V; Narciso P; Antinori A; Stuyver L; Perno CF; Ceccherini-Silberstein F
J Infect Dis; 2012 Feb; 205(4):557-67. PubMed ID: 22238474
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
[TBL] [Abstract][Full Text] [Related]
17. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.
Underwood MR; Johns BA; Sato A; Martin JN; Deeks SG; Fujiwara T
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):297-301. PubMed ID: 22878423
[TBL] [Abstract][Full Text] [Related]
18. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.
Heredia A; Hassounah S; Medina-Moreno S; Zapata JC; Le NM; Han Y; Foulke JS; Davis C; Bryant J; Redfield RR; Wainberg MA
J Antimicrob Chemother; 2017 Sep; 72(9):2570-2573. PubMed ID: 28637235
[TBL] [Abstract][Full Text] [Related]
19. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
20. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C
J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
